3 days popular7 days popular1 month popular3 months popular

Trial Compares Ways To Elicit Patient Values About Prostate-Specific Antigen Screening

, M.D., M.P.H., of the University of North Carolina, , and colleagues conducted a randomized clinical in in which men underwent a values clarification task and then chose the most important attribute for prostate-specific antigen () screening.  

Men must consider how they value different potential outcomes to make good about , according to the study. The trial included 911 men (ages 50 to 70 years) from the United States and Australia who had average risk for prostate cancer.  

“The participants who received the rating and ranking task were more likely to report reducing the chance of death from prostate cancer as being most important (54.4 percent) … Further studies with more distal outcome measures are needed to determine the best method of values clarification, if any, for decisions such as whether to undergo screening with PSA.”


JAMA Internal Medicine. Published online February 11, 2013. doi:10.1001/jamainternmed.2013.2651.